SOAT1 and inflammatory bowel disease: Although pan-JAK-inhibitor tofacitinib, also known as IBD, was effective in UC patients but not in Crohn’s patients, suggesting that the JAK/STAT signaling pathway may induce more severe inflammation in UC.